Cochrane · systematic review · CD011983
Supervised dosing with a long‐acting opioid medication in the management of opioid dependence
Saulle, R, Vecchi, S, Gowing, L · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Drugs and AlcoholAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 14.3%Very low 3 · 42.9%Low 3 · 42.9%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Supervised dosing with a long‐acting medication compared to unsupervised consumption for opioid dependence
Population: patients with opioid dependence
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Retention ‐ retention at the end of treatment (number of participants) Supervised dosing with a long‐acting medication vs unsupervised consumption | RR 0.99 [0.88, 1.12] | 4 studies · 716 participants | Low Downgraded: risk of bias |
Retention ‐ retention at 3 months (number of participants) Supervised dosing with a long‐acting medication vs unsupervised consumption | RR 0.94 [0.84, 1.05] | 3 studies · 472 participants | Low Downgraded: risk of bias |
Adverse serious events (any) (number of participants) Supervised dosing with a long‐acting medication vs unsupervised consumption | RR 0.63 [0.1, 3.86] | 2 studies · 363 participants | Very low Downgraded: risk of bias |
Abstinence from unsanctioned opioid use (number of participants with urine drug screen or self‐report use) Supervised dosing with a long‐acting medication vs unsupervised consumption | no estimate extracted | 1 study · 293 participants | Very low Downgraded: risk of bias |
Diversion (number of participants) Supervised dosing with a long‐acting medication vs unsupervised consumption | no estimate extracted | 1 study · 293 participants | Very low Downgraded: risk of bias |
Frequency of unsanctioned opioid use at the end of the intervention (number of days) Supervised dosing with a long‐acting medication vs unsupervised consumption | no estimate extracted | 0 studies · 0 participants | Ungraded |
Mortality ‐ (number of participants) Supervised dosing with a long‐acting medication vs unsupervised consumption | no estimate extracted | 1 study · 230 participants | Low |